Perioperative Pembrolizumab Expands in Bladder Cancer
FDA expanded perioperative enfortumab vedotin plus pembrolizumab to cystectomy-eligible muscle-invasive bladder cancer, regardless of cisplatin eligibility, broadening pre- and postoperative treatment options.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.